USOR #17132

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy after Definitive Local Therapy in Patients with High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (WO40242)